Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate vs Levetiracetam for NESIS in Chronic Subdural Hematoma
NCT04759196Phase 4Unknown
- Sponsor
- Université de Sherbrooke
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of topiramate in chronic subdural hematoma (CSDH) (4 arms), sponsored by Université de Sherbrooke. Primary endpoint: Number of Transient Neurological Symptoms reported at 6 months. Status: unknown.
02
Drugs
topiramate
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT04759196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759196.